What is NMN?
NMN is nicotinamide mononucleotide, a biosynthetic precursor used by cells to make NAD+.[1][2][5]
The default oral protocol uses the lowest NMN dose from a randomized 60-day dose-ranging trial and does not borrow an NR or direct NAD+ presentation.[1][2][5]
What NMN is investigated for
NMN evidence is grouped by practical use case and oral, sublingual, intravenous, topical, and transdermal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
NAD+ biomarker support
Oral
NAD+ biomarker support
Oral
Oral NAD+ biomarker restoration is the most reproducible NMN finding; it is not proof of symptom, disease, or longevity benefit.[7][8][13]
Glucose and metabolic health
Oral
Glucose and metabolic health
Oral
NMN is not established as a treatment for insulin resistance, diabetes, dyslipidemia, or weight loss.[7][8]
Physical function and exercise performance
Oral
Physical function and exercise performance
Oral
Physical-performance effects remain limited and should not be promised for healthy users or generalized across populations.[9][10]
Vascular health
Oral
Vascular health
Oral
Sleep and fatigue
Oral
Sleep and fatigue
Oral
Evidence snapshot
Overall confidence
Oral NMN has multiple controlled human studies with biomarker and short-term safety data.[1][2][5]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Human trials include daily 250 mg and dose-ranging 300, 600, and 900 mg regimens.[1][2][5]
Animal / preclinical
Preclinical biology is extensive, but it does not replace the route-matched human oral evidence.[1][2][5]
Mechanism support
Forms & administration
NMN has oral capsule and tablet presentations, alongside investigational sublingual and intravenous formulations. Experimental wound gels and assisted skin-delivery systems have mainly laboratory or animal evidence. Each form needs its own preparation and amount; an ongoing intravenous course is not established.[1][25][3][30][31][32]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
What to expect
First 1–2 weeks
Blood NAD+ and related metabolites can rise within early study windows, but a biomarker response does not predict a noticeable clinical effect.[14][2][12]
Weeks 4–8
Many trials reassess NAD+ biomarkers, tolerability, and exploratory metabolic or physical outcomes in this range; lack of a symptom change is compatible with the evidence.[1][7][8]
Weeks 8–12
Sleep, fatigue, walking, and vascular outcomes in longer small trials are mixed and population-specific; they are not guaranteed milestones.[4][18][20]
After stopping
The durability of biomarker or symptom changes after stopping is not consistently mapped; NMN should not be assumed to create a permanent NAD+ increase.[6][13]
Safety profile
Short oral trials and recent pooled analyses generally report acceptable tolerability without a consistent excess serious-adverse-event pattern, but multi-year use, special populations, and product-to-product quality remain incompletely characterized.[1][2][17][12]
Who NMN is not for
Route-specific avoid and medical-review notes:
Regulatory status
United States
NMN is not FDA-approved as a drug. In a September 2025 response, FDA concluded that NMN is not excluded from the dietary-supplement definition; that conclusion is not drug approval or blanket approval of individual products.[28][33]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Oral | Not Approved NMN is not FDA-approved as a oral drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval.[33] | Not Listed NMN does not have FDA-approved oral dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific.[33] |
Oral
FDA drug approval
Not ApprovedNMN is not FDA-approved as a oral drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval.[33]
503A compounding
Not ListedNMN does not have FDA-approved oral dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific.[33]
International
The European Commission has treated NMN as a novel food requiring authorization; an application or consultation status is not the same as placement on the authorized Union list.[29]
Sports & competition
Tested athletes should obtain sport-specific review for non-approved NAD-pathway products.[35]
How it works
NMN sits immediately upstream of NAD+ in the salvage pathway, which is why oral studies measure circulating NAD-related metabolites after supplementation.[1][2][5]
Oral exposure and metabolism differ from direct NAD+ administration and from nicotinamide riboside, so the molecule keeps its own dose and route record.[1][2][5]
Research gaps & open questions
What the current literature has not yet settled about NMN:
Longer controlled trials need to test clinical outcomes rather than only NAD-related biomarkers.[1][2][5]
Independent trials should compare multiple NMN amounts and better define safety in older adults and people with chronic conditions.[1][2][5]
Metabolic studies need to resolve why the muscle insulin-sensitivity signal in one population has not translated into consistent pooled glucose or lipid outcomes.[15][7][8]
Physical-function and sleep signals need replication with clearly chosen outcomes, clinically meaningful effect thresholds, and diverse populations.[9][10][20]
Multi-year safety, post-discontinuation durability, and outcomes in pregnancy, cancer, and polypharmacy remain insufficiently studied.[26][13][12]
Common questions
Is NMN direct NAD+?
Does NMN have proven anti-aging or longevity benefits?
Does NMN improve blood sugar or insulin resistance?
Does NMN reliably improve exercise or physical performance?
Is NMN banned as a dietary supplement in the United States?
FDA's September 2025 response concluded that NMN is not excluded from the dietary-supplement definition. That does not make NMN an FDA-approved drug or approve every product.[28]
Myths & misconceptions
Myth
NMN and NR are interchangeable names.
Myth
A higher blood NAD+ result proves that NMN is improving health.
Myth
Dietary-supplement status means NMN is FDA-approved.
History & discovery
NMN is a nucleotide intermediate in NAD+ biosynthesis rather than a peptide. Human research began with short oral safety and metabolism studies, then expanded into randomized trials of NAD+ biomarkers, insulin sensitivity, physical function, vascular measures, sleep, and disease-specific questions. Biomarker engagement is more consistent than downstream clinical benefit.[6][14][26][13]
A small study in healthy men described short-term oral safety and nicotinamide-metabolite handling.[14]
Trials evaluated insulin sensitivity, aerobic capacity, sleep, physical performance, blood NAD+, and arterial stiffness.[15][16][4][18]
Meta-analyses found reliable NAD+ biomarker engagement but heterogeneous or mostly null cardiometabolic outcomes, while new disease-specific trials remained early.[7][8][23][12]
35 citations
Show citationsHide citations
- [1]The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trialGeroScience, 2022. human clinical.
- [2]Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy SubjectsFrontiers in Nutrition, 2022. human clinical.
- [3]Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy IndividualsNutrients, 2022. human clinical.
- [4]Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese AdultsNutrients, 2022. human clinical.
- [5]The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humansNature Metabolism, 2026. human clinical.
- [6]Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future DirectionsJournal of Clinical Endocrinology & Metabolism, 2023. review.
- [7]Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trialsCritical Reviews in Food Science and Nutrition, 2025. review.
- [8]Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled TrialsCurrent Diabetes Reports, 2024. review.
- [9]Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide: A Systematic Review of Randomized Control TrialsCureus, 2024. review.
- [10]The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-AnalysisJournal of Cachexia, Sarcopenia and Muscle, 2025. review.
- [11]Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsNutrients, 2026. review.
- [12]Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-AnalysisNutrients, 2026. review.
- [13]NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidenceAgeing Research Reviews, 2026. review.
- [14]Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese menEndocrine Journal, 2020. human clinical.
- [15]Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic womenScience, 2021. human clinical.
- [16]Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind studyJournal of the International Society of Sports Nutrition, 2021. human clinical.
- [17]Safety evaluation of beta-nicotinamide mononucleotide oral administration in healthy adult men and womenScientific Reports, 2022. human clinical.
- [18]Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trialScientific Reports, 2023. human clinical.
- [19]Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese menEndocrine Journal, 2024. human clinical.
- [20]Ingestion of beta-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled studyGeroScience, 2024. human clinical.
- [21]MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older AdultsThe Journals of Gerontology: Series A, 2023. human clinical.
- [22]Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind studyGeriatrics & Gerontology International, 2023. human clinical.
- [23]Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trialNature Medicine, 2026. human clinical.
- [24]Effect of Nicotinamide Mononucleotide on Retinal Thickness of Older Patients With Diabetes Mellitus: A Placebo-Controlled, Double-Blind StudyGeriatrics & Gerontology International, 2026. human clinical.
- [25]Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult menScientific Reports, 2026. human clinical.
- [26]The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an UpdateAdvances in Nutrition, 2023. review.
- [27]NAD+ Precursors Nicotinamide Mononucleotide and Nicotinamide Riboside: Potential Dietary Contribution to HealthCurrent Nutrition Reports, 2023. review.
- [28]FDA response regarding the dietary supplement status of beta-nicotinamide mononucleotideU.S. Food and Drug Administration, 2025-09-29. regulatory.
- [29]Consultation process on novel food status: beta-nicotinamide mononucleotideEuropean Commission. regulatory.
- [30]Temperature-sensitive hydrogel dressing loaded with nicotinamide mononucleotide accelerating wound healing in diabetic mice.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023 Nov. animal.
- [31]Ex Vivo Transdermal Delivery of Nicotinamide Mononucleotide Using Polyvinyl Alcohol Microneedles.Polymers, 2023 Apr 25. ex vivo.
- [32]NAD+ modulation with nicotinamide mononucleotide coated 3D printed microneedle implants.Journal of materials chemistry. B, 2025 Mar 12. ex vivo.
- [33]Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration. official guidance.
- [34]FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-RegulatedU.S. Food and Drug Administration. official guidance.
- [35]The 2026 List of Prohibited Substances and MethodsWorld Anti-Doping Agency, 2026. regulatory.


